Member Login
Home
About Us
Officers
Contact Us
Corporate Members
Become a Corporate Member
Events
2024 Annual Meeting Exhibitors
Targeted Oncology™ Community Case Forum™ - April 25
Virtual CME - May 7
Past Annual Meeting Highlights
Membership
Resources
Job Bank
Advertise a Job
FDA Approvals
Podcasts
Find an Oncologist
Useful Links
Corporate Members
FDA Approvals
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
Now Approved
Breyanzi®—a CAR T cell therapy option for patients with R/R CLL or SLL2
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
FDA has approved BOSULIF (bosutinib) for a new indication and has also approved a new formulation.
Home
About Us
Officers
Contact Us
Corporate Members
Become a Corporate Member
Events
2024 Annual Meeting Exhibitors
Targeted Oncology™ Community Case Forum™ - April 25
Virtual CME - May 7
Past Annual Meeting Highlights
Membership
Resources
Job Bank
Advertise a Job
FDA Approvals
Podcasts
Find an Oncologist
Useful Links
Pennsylvania Society of Oncology and Hematology